Acinetobacter Species: Resistance Update and Treatment Options

2007 ◽  
pp. 125-148 ◽  
Author(s):  
Lisa L. Maragakis ◽  
Trish M. Perl
Keyword(s):  
Treatment Options ◽  
Acinetobacter Species

An Update on the Management of Nosocomial Pneumonia

2008 ◽  
Vol 21 (5) ◽  
pp. 380-389 ◽  
Author(s):  
Rahul Gupta ◽  
Kurt A. Wargo
Keyword(s):  
Nosocomial Pneumonia ◽  
Stenotrophomonas Maltophilia ◽  
Methicillin Resistant Staphylococcus Aureus ◽  
Early Recognition ◽  
Treatment Options ◽  
Acinetobacter Species ◽  
Hospital Acquired Infection ◽  
Appropriate Treatment ◽  
Dosing Strategies ◽  
Hospital Acquired

Nosocomial pneumonia is the second most common hospital-acquired infection, after urinary tract infection; however, it carries with it a mortality rate estimated to be between 20% and 50%. Furthermore, patients with nosocomial pneumonia are hospitalized for an additional 7 to 9 days with an attributable cost of $40 000 or more per patient compared to patients without nosocomial pneumonia. While treatment options vary, initial empiric treatment of nosocomial pneumonia should include antimicrobials that will have activity against the organisms that will likely be encountered, including, but not limited to, methicillin-resistant Staphylococcus aureus, Pseudomonas aeruginosa, Acinetobacter species, Klebsiella pneumoniae, Enterobacter subspecies, Serratia marcescens, and Stenotrophomonas maltophilia. During a time of increasing resistance, it is crucial that early recognition along with appropriate treatment and dosing strategies are employed to achieve successful outcomes. The goal of this article is to update clinicians about nosocomial pneumonia and provide information regarding caveats to selecting and dosing antimicrobials, so informed decisions can be made when treating this serious condition.

Treatment Options for??Multidrug-Resistant Acinetobacter Species

Drugs ◽  
2008 ◽  
Vol 68 (2) ◽  
pp. 165-189 ◽  
Author(s):  
Jacob Gilad ◽  
Yehuda Carmeli
Keyword(s):  
Treatment Options ◽  
Multidrug Resistant ◽  
Acinetobacter Species

scholarly journals Sensitivity Patterns of Bacterial Pathogens Isolated from Blood Cultures of Under-Five Children with Pneumonia and Clinical Sepsis

Life ◽  
2021 ◽  
Vol 11 (5) ◽  
pp. 450
Author(s):  
Sufia Islam ◽  
Ashiqur Rahman Akand ◽  
Tasnova Tasnim Nova ◽  
Christian Lehmann ◽  
Mohammod Jobayer Chisti
Keyword(s):  
Treatment Options ◽  
Clinical Signs ◽  
Antibiotic Sensitivity ◽  
Salmonella Typhi ◽  
Multidrug Resistant ◽  
Blood Cultures ◽  
Bacterial Strains ◽  
Coagulase Negative Staphylococci ◽  
Acinetobacter Species ◽  
Clinical Sepsis

Treatment options for pneumonia and sepsis by antibiotics are limited due to the development of multidrug-resistant bacterial strains. This unmatched case-control study determined the antibiotic sensitivity against bacterial isolates obtained from septic and nonseptic children with pneumonia. Children of either sex aged 0–59 months with a history of cough or shortness of breath and radiologically confirmed pneumonia were enrolled in this study. Cases with clinical signs of sepsis at admission (n = 151) were compared to cases without sepsis as controls (n = 107). A total of 205 children had a performance of blood culture, with 123 children suffering from clinical sepsis. Blood cultures showed bacterial growth in 19% of the septic samples, with 8% coagulase-negative staphylococci and 2.4% Acinetobacter species. Only 1.6% of the cases were infected by Streptococcus pneumonia, Haemophilus influenzae, Salmonella typhi and Klebsiella. In contrast, children without sepsis presented positive blood cultures with growth of Salmonella typhi in 2.4% of the cases and growth of Klebsiella in 1.2%. Bacteria were sensitive to imipenem in 100% of the cases (86% for meropenem, 83% for ceftazidime and 76% for ciprofloxacin). The mortality rate was significantly higher in children with pneumonia complicated by sepsis (odds ratio (OR) = 3.02, 95% confidence interval (CI), 1.11–8.64, p < 0.027). Knowledge about specific laboratory characteristics in children with pneumonia will facilitate an early diagnosis and treatment of sepsis and reduce mortality.

scholarly journals blaIMP and blaVIM mediated carbapenem resistance in Pseudomonas and Acinetobacter species in India

2012 ◽  
Vol 6 (11) ◽  
pp. 757-762 ◽  
Author(s):  
M Shanthi Amudhan ◽  
Uma Sekar ◽  
Arunagiri Kamalanathan ◽  
Sekar Balaraman
Keyword(s):  
Clinical Laboratory ◽  
Ethylenediaminetetraacetic Acid ◽  
Treatment Options ◽  
Carbapenem Resistance ◽  
Pseudomonas Stutzeri ◽  
Acinetobacter Species ◽  
Carbapenem Resistant ◽  
Rapid Spread ◽  
The Common ◽  
Polymerase Chain

Introduction: The emergence and rapid spread of blaIMP and blaVIM metallo-beta-lactamase (MBL) producing Gram-negative bacteria causing nosocomial infections are of concern worldwide due to limited treatment options. Methodology: A total of 179 nonreplicate, consecutive, carbapenem resistant Pseudomonas aeruginosa (61), Acinetobacter baumannii (116), Acinetobacter lwoffii (1) and Pseudomonas stutzeri (1) isolated from patients hospitalized for 48 hours or more were included in the study. The minimum inhibitory concentrations (MIC) to imipenem and meropenem were determined and interpreted according to Clinical Laboratory Standards Institute guidelines. The Modified Hodge Test (MHT) and inhibitor potentiated disk diffusion tests with ethylenediaminetetraacetic acid (EDTA) were used for screening of carbapenamases and MBL production respectively. Polymerase chain reaction (PCR) was performed for the detection of MBL (blaVIM and blaIMP) genes. Gene sequencing was performed for representative isolates. Results: MHT was positive in 94.4% (n = 169). MBL screening with EDTA was positive in 80.4% (n = 144). MBL genes bla VIM and bla IMP were detected in 92 (51.4%) isolates. Bla VIM alone was detected in 89 isolates while two isolates had bla IMP alone. One isolate had both bla VIM and bla IMP. Among the P. aeruginosa, 36 carried the MBL gene. In A. baumannii, 54 carried the MBL gene. Bla VIM was found in P. stutzeri and A. lwoffii isolates. Conclusion: Carbapenem resistance in P. aeruginosa and A. baumannii is chiefly mediated by MBL production. The common MBL gene is the blaVIM.

scholarly journals Prevalence of Tigecycline resistance in Multidrug-Resistant Acinetobacter species isolates from clinical specimens

2019 ◽  
Vol 7 (2) ◽  
pp. 42-47
Author(s):  
Moni Mahto ◽  
Banodita Acharya Dhungel
Keyword(s):  
Acinetobacter Baumannii ◽  
Antibiotic Susceptibility ◽  
Therapeutic Option ◽  
Treatment Options ◽  
Polymyxin B ◽  
Multidrug Resistant ◽  
Acinetobacter Baumanii ◽  
Acinetobacter Species ◽  
Institutional Review ◽  
Almost All

Background and Objectives: Acinetobacter baumanii is ubiquitous, aerobic non fermentative, gram negative cocobacilli, emerging globally as an important cause of nosocomial infection. This study was conducted to determine the prevalence and antibiogram of clinically isolated multidrug-resistant Acinetobacter species. Material and methods: Antibiotic susceptibility of 93 Acinetobacter baumannii isolates were performed against ampicillin, ampicillin/sulbactam, piperacillin/tazobactam, ceftazidime, cefepime, ceftriaxone, cefotaxime, ciprofloxacin, levofloxacin, amikacin, gentamicin, imipenem, meropenem, tigecycline, polymyxin B and colistin as per standard methods in microbiology laboratory of Nepal Mediciti Hospital, Kathmandu, Nepal from January to December 2018. Ethical clearance was taken from the Institutional review committee of Nepal Mediciti Hospital. Results: A total of 93 Acinetobacter baumannii isolates were obtained from sputum, blood, pus, wound swabs , catheter tips and others. Antibiotic susceptibility analyses of the isolates revealed that the resistance to ampicillin was most common (100%), followed by cefotaxime (75.2%), ceftazidime (74.1%), ampicillin/sulbactam (73.1%), cefepime (67.7%). However, almost all isolates were susceptible to tigecycline (100%), followed by colistin (98.9%), and polymyxin B (87.0%). Conclusion: The present study showed the increasing trends of resistance of Acinetobacter speciesto various classes of antimicrobials. Treatment options for infections due to MDR and XDR Acinetobacter baumanii are very limited and tigecycline and colistin may be considered as one of the therapeutic option for the treatment of hospital acquired infections

scholarly journals STUDY OF RESISTANCE FOR RECENTLY MARKETED CARBAPENEM DRUG AMONG HOSPITALISED PATIENTS IN SANA'A, YEMEN

2018 ◽  
Author(s):  
Ali Alyahawi ◽  
Ali Alkaf ◽  
Rashad Alnamer ◽  
Taha Alnosary
Keyword(s):  
Escherichia Coli ◽  
Pseudomonas Aeruginosa ◽  
Treatment Options ◽  
Public Health Problem ◽  
Carbapenem Resistance ◽  
Klebsiella Pneumonia ◽  
Klebsiella Species ◽  
Acinetobacter Species ◽  
Hospitalised Patients ◽  
Recent Emergence

Carbapenem resistance is a major and a future public health problem globally. It occurs mainly among Gram-negative bacteria.  Meropenem is the recently marketed carbapenem drug in Yemen. However, recent emergence of carbapenem-resistant isolates has become a major healthcare concern. The current study was designed to estimate the prevalence of meropenem resistance among hospitalised patients in Sana'a, Yemen. The study was performed at a local hospital in Sana’a, Yemen. The records of Meropenem susceptibility were taken for hospitalised patients. A total of 443 Meropenem susceptibility samples were collected from August, 2017 to July, 2018. The meropenem susceptibility was studied against several isolated pathogens. Out of 443 study sample, 316 (71.3%) were meropenem sensitive isolates and 25.3% of samples were resistant. The Escherichia coli isolates were observed in 27.5% of sample, followed by Pseudomonas aeruginosa (19.6%). 36.4% of total meropenem sensitive isolates (115/316) were Escherichia coli. In addition, 94.3% (115/122) of Escherichia coli isolates were meropenem sensitive. However, the Klebsiella species had higher meropenem resistance than other pathogens (30/112; 26.8%). Moreover, 89.7% (26/29) of Acinetobacter species isolates were meropenem resistant. 82.4% (42/51) of Klebsiella pneumonia isolates were meropenem sensitive and 32.2% (28/87) of Pseudomonas aeruginosa were meropenem resistance. In the present study, 34.5% (109/316) of meropenem sensitive isolates were from blood cultures, followed by sputum cultures (23.7%; 75/316). However, 58% (65/112) of sputum culture isolates were meropenem resistance. This study concluded that the percentage of resistance to meropenem was high (25.3%) and cannot be neglected. Continued surveillance to closely monitor trends as well as infection control and antibiotic stewardship activities are necessary to preserve treatment options. A more careful monitoring for use of broad-spectrum antibiotics should be instituted.

scholarly journals Biodegradation of Total Petroleum Hydrocarbon by Molecularly Identified Bacteria Isolated From an Oilfield Wastewater in Nigeria

2020 ◽  
Vol 5 (2) ◽  
pp. 1-7
Author(s):  
Oyibo N
Keyword(s):  
Crude Oil ◽  
Mixed Culture ◽  
Petroleum Hydrocarbon ◽  
Treatment Options ◽  
Total Petroleum Hydrocarbon ◽  
Control Individual ◽  
Individual Species ◽  
Microbiological Analysis ◽  
Acinetobacter Species ◽  
Enterobacter Hormaechei

Biodegradation of petroleum hydrocarbon is a complex process that depends on the nature and on the amount of the hydrocarbon present. Many microbial organisms have been shown to possess the capacity to biodegrade various components of hydrocarbon. Hence this study was aimed at assessing the potential of bacterial species isolated from oilfield wastewater to biodegrade total petroleum hydrocarbon in crude oil. Oilfield wastewater was collected from an onshore oil production platform. Standard procedures were observed during collection and microbiological analysis of wastewater samples. Bacteria isolated were identified using conventional and molecular methods. The biodegradation set up was done using six conical flasks containing basal medium of mineral salt broth and crude oil as the source of energy for growth. Bacteria isolated were identified as Acinetobacter species, Enterobacter hormaechei, Myroides odaratimimus and Lysinibacillus species. Flasks of experimental set ups were inoculated with 1ml of individual isolate and mixed culture except the control. The biodegradation of TPH were periodically monitored for 35 days using Gas Chromatography (GC). Total viable counts (CFU/ML) obtained during the experiment ranged from 0-1.8×105, 1.65×105 - 3.2×106, 1.90×106 -1.28×107, 1.52×106 – 8.9×106, 1.13×106 – 1.48×107, 3.4×106 – 2.19×107 in control, Acinetobacter species, Enterobacter hormaechei, Myroides odaratimimus, Lysinibacillus species and the mixed culture treatment options respectively. The initial concentration of TPH at day 1 was 3241.47mg/l. At the end of the experiment (day 35), control, Acinetobacter species, Enterobacter hormaechei, Myroides odaratimimus, Lysinibacillus speccies and the mixed culture treatment options recorded final concentration of 2823.33, 363.72, 383.44, 284.55, 472.70 and 212.21mg/l respectively. Highest percentage removal of 93.5% was observed in the mixed culture while the least of 12.9% was observed in the control; individual species showed significant reduction in TPH with different capability. Results showed that bacteria isolated from oilfield wastewater have the ability to degrade total petroleum hydrocarbon (TPH) and can be used in the clean-up of crude oil contaminated area.

The Collaborative Network Approach: a model for advancing patient-centric research for Castleman disease and other rare diseases

2019 ◽  
Vol 3 (1) ◽  
pp. 97-105
Author(s):  
Mary Zuccato ◽  
Dustin Shilling ◽  
David C. Fajgenbaum
Keyword(s):  
Rare Diseases ◽  
Treatment Options ◽  
Castleman Disease ◽  
High Impact ◽  
Collaborative Network ◽  
Network Approach ◽  
Grant Applications ◽  
Research Questions ◽  
Novel Strategy ◽  
Patient Centric

Abstract There are ∼7000 rare diseases affecting 30 000 000 individuals in the U.S.A. 95% of these rare diseases do not have a single Food and Drug Administration-approved therapy. Relatively, limited progress has been made to develop new or repurpose existing therapies for these disorders, in part because traditional funding models are not as effective when applied to rare diseases. Due to the suboptimal research infrastructure and treatment options for Castleman disease, the Castleman Disease Collaborative Network (CDCN), founded in 2012, spearheaded a novel strategy for advancing biomedical research, the ‘Collaborative Network Approach’. At its heart, the Collaborative Network Approach leverages and integrates the entire community of stakeholders — patients, physicians and researchers — to identify and prioritize high-impact research questions. It then recruits the most qualified researchers to conduct these studies. In parallel, patients are empowered to fight back by supporting research through fundraising and providing their biospecimens and clinical data. This approach democratizes research, allowing the entire community to identify the most clinically relevant and pressing questions; any idea can be translated into a study rather than limiting research to the ideas proposed by researchers in grant applications. Preliminary results from the CDCN and other organizations that have followed its Collaborative Network Approach suggest that this model is generalizable across rare diseases.

Establishing a Group Educational Session for Hyperacusis Patients

2019 ◽  
Vol 28 (2) ◽  
pp. 245-250
Author(s):  
Ann E. Perreau ◽  
Richard S. Tyler ◽  
Patricia C. Mancini ◽  
Shelley Witt ◽  
Mohamed Salah Elgandy
Keyword(s):  
Therapeutic Process ◽  
Treatment Options ◽  
Clinical Group ◽  
Education Session ◽  
Group Approach ◽  
Treatment Protocols ◽  
Educational Session ◽  
Evidence Based Treatment ◽  
Relationship Of ◽  
The Relationship

Purpose Audiologists should be treating hyperacusis patients. However, it can be difficult to know where to begin because treatment protocols and evidence-based treatment studies are lacking. A good place to start in any tinnitus and hyperacusis clinic is to incorporate a group educational session. Method Here, we outline our approach to establishing a hyperacusis group educational session that includes specific aspects of getting to know each patient to best meet their needs, understanding the problems associated with hyperacusis, explaining the auditory system and the relationship of hyperacusis to hearing loss and tinnitus, describing the influence of hyperacusis on daily life, and introducing treatment options. Subjective responses from 11 adults with hyperacusis, who participated in a recent clinical group education session, were discussed to illustrate examples from actual patients. Conclusions Due to the devastating nature of hyperacusis, patients need to be reassured that they are not alone and that they can rely on audiologists to provide support and guidance. A group approach can facilitate the therapeutic process by connecting patients with others who are also affected by hyperacusis, and by educating patients and significant others on hyperacusis and its treatment options. Supplemental Material https://doi.org/10.23641/asha.8121197

Sign in / Sign up

Export Citation Format

Share Document